

CVD biomarkers and kidney function

Cardiovascular disease protein biomarkers are associated with kidney function: the Framingham Heart Study

Amena Keshawarz, PhD, MPH;^{a,b} Shih-Jen Hwang, PhD;^{a,b} Gha Young Lee, BS;^{a,b} Zhi Yu, MB, PhD;^{c,d,e} Chen Yao, PhD;^{a,b} Anna Köttgen, MD, MPH^{f,g}; Daniel Levy, MD^{a,b}

Affiliations:

^a Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

^b Framingham Heart Study, Framingham, MA, USA

^c Broad Institute of Harvard and MIT, Cambridge, Massachusetts

^d Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

^e Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland

^f Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany

^g Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Short title: CVD biomarkers and kidney function

Corresponding author:

Daniel Levy, MD, Framingham Heart Study

73 Mt. Wayte Avenue

Framingham, MA 01702

CVD biomarkers and kidney function

Phone: (508) 872-6556

levyd@nih.gov

Number of tables: 3

Number of figures: 1

Abstract word count: 297

Body text word count: 3,890

Keywords: chronic kidney disease, cardiovascular disease, proteomics, Mendelian randomization

CVD biomarkers and kidney function

1 **Background.** Biomarkers common to chronic kidney disease (CKD) and cardiovascular
2 disease (CVD) may reflect early impairments underlying both diseases.

3 **Methods.** We evaluated associations of 71 CVD-related plasma proteins measured in
4 2,873 Framingham Heart Study (FHS) Offspring cohort participants with cross-sectional
5 continuous eGFR and with longitudinal change in eGFR from baseline to follow-up (Δ eGFR).
6 We also evaluated the associations of the 71 CVD proteins with the following dichotomous
7 secondary outcomes: prevalent CKD stage ≥ 3 (cross-sectional), new-onset CKD stage ≥ 3
8 (longitudinal), and rapid decline in eGFR (longitudinal). Proteins significantly associated with
9 eGFR and Δ eGFR were subsequently validated in 3,951 FHS Third Generation cohort
10 participants and were tested using Mendelian randomization (MR) analysis to infer putatively
11 causal relations between plasma protein biomarkers and kidney function.

12 **Results.** In cross-sectional analysis, 37 protein biomarkers were significantly associated
13 with eGFR at $FDR < 0.05$ in the FHS Offspring cohort and 20 of these validated in the FHS Third
14 Generation cohort at $p < 0.05/37$. In longitudinal analysis, 27 protein biomarkers were
15 significantly associated with Δ eGFR at $FDR < 0.05$ and 12 of these were validated in the FHS
16 Third Generation cohort at $p < 0.05/27$. Additionally, 35 protein biomarkers were significantly
17 associated with prevalent CKD, five were significantly associated with new-onset CKD, and 17
18 were significantly associated with rapid decline in eGFR. MR suggested putatively causal
19 relations of melanoma cell adhesion molecule (MCAM; -0.011 ± 0.003 mL/min/1.73m², $p = 5.11E-$
20 5) and epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1; $-$
21 0.006 ± 0.002 mL/min/1.73m², $p = 0.0001$) concentration with eGFR.

22 **Discussion/Conclusions:** Eight protein biomarkers were consistently associated with
23 eGFR in cross-sectional and longitudinal analysis in both cohorts and may capture early kidney

CVD biomarkers and kidney function

24 impairment; others were implicated in association and causal inference analyses. A subset of
25 CVD protein biomarkers may contribute causally to the pathogenesis of kidney impairment and
26 should be studied as targets for CKD treatment and early prevention.

27

CVD biomarkers and kidney function

28 **Introduction**

29 Chronic kidney disease (CKD) affects approximately 15% of the United States
30 population, including more than 30% of adults over the age of 65 years.^{1,2} Additionally, CKD is
31 among the leading global causes of mortality.³ CKD is characterized by kidney damage and
32 impairment of filtration, which can culminate in kidney failure and death.⁴ Kidney function is
33 frequently assessed clinically using estimated glomerular filtration rate (eGFR) based on serum
34 creatinine concentration.⁵ Early stages of CKD are often asymptomatic, and as such, CKD may
35 not be diagnosed until the development of substantial and often irreversible kidney dysfunction.
36 Thus, the identification of biomarkers of subclinical CKD that detect early kidney impairment
37 when treatment is more likely to be beneficial could prove to be important for disease prevention
38 and treatment.

39 CKD and cardiovascular disease (CVD) share common risk factors including diabetes
40 mellitus (DM) and hypertension,⁶ which are highly prevalent in adults with CKD and are
41 associated with subclinical and clinical CVD risk.^{7,8} More than 50% of CKD cases in the United
42 States are attributable to DM,⁹ and estimates of hypertension prevalence in patients with CKD
43 range between 40% and 60%.¹⁰⁻¹² Other shared mechanisms contributing to CKD and CVD
44 include inflammation,¹³ activation of the renin-angiotensin-aldosterone system,¹³ oxidative
45 stress,^{14,15} and endothelial dysfunction.¹⁴ Identifying biomarkers of kidney function may provide
46 insights into shared mechanisms of CKD and CVD.

47 Given the complex relationship between CKD and CVD, we aimed to identify protein
48 biomarkers of kidney dysfunction and CKD. To this end, we evaluated the associations of 71
49 CVD-related plasma proteins with CKD traits. These proteins were measured in 7,184
50 Framingham Heart Study (FHS) participants as a part of the Systems Approach to Biomarker

CVD biomarkers and kidney function

51 Research in Cardiovascular Disease (SABRe CVD) Initiative.¹⁶ We tested the cross-sectional
52 and longitudinal associations of the 71 CVD proteins with kidney function traits. We also
53 conducted causal inference analyses using genetic variants associated with these proteins in
54 conjunction with genetic variants from a recently published large GWAS meta-analysis of
55 kidney function traits.¹⁷

56 **Materials and Methods**

57 Discovery sample

58 The discovery sample for this investigation included participants in the FHS Offspring¹⁸
59 cohort who attended the seventh examination cycle (1998-2001; baseline visit). At this visit,
60 serum and plasma samples were collected for measurement of serum creatinine and the 71 CVD-
61 related plasma proteins as part of the SABRe CVD Initiative.¹⁶ Participants with a baseline
62 eGFR ≥ 60 mL/min/1.73m² who attended the FHS Offspring eighth examination cycle (2005-
63 2008; follow-up visit) where a second serum creatinine measurement was obtained were
64 included in the longitudinal analysis of kidney function.

65 Participants with a medical record-confirmed diagnosis of heart failure or myocardial
66 infarction at the baseline visit were excluded due to the effect of these diagnoses on biomarker
67 concentrations, yielding a final sample of 2,873 participants for cross-sectional analysis. There
68 were 2,393 participants who attended the follow-up examination and were eligible for inclusion
69 in the longitudinal analyses. All study protocols were approved by the Boston University
70 Medical Center institutional review board, and all study participants provided their
71 informed consent to participate in FHS research investigations. An overview of the study design
72 is presented in **Figure 1**.

73 Clinical examination and definitions

CVD biomarkers and kidney function

74 Medical history and fasting blood samples were collected from all study participants at an
75 in-person research center examination.¹⁹ Body mass index (BMI) was calculated as the ratio of
76 the participant's weight in kilograms to the square of height in meters. DM status was defined by
77 fasting blood glucose concentration ≥ 126 mg/dL or use of hypoglycemic medication.²⁰
78 Hypertension was defined by systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90
79 mmHg, or use of antihypertensive medication.²¹ Participants were defined as current smokers if
80 they reported smoking at least one cigarette per day on average during the previous year.
81 Prevalent CVD at the baseline study visit was defined as angina pectoris, coronary insufficiency,
82 cerebrovascular accident, atherothrombotic infarction of brain, transient ischemic attack, cerebral
83 embolism, intracerebral hemorrhage, subarachnoid hemorrhage, or intermittent claudication.

84 SABRe CVD biomarkers

85 Details of measurement of the 71 CVD-related proteins evaluated in this study have been
86 described previously.¹⁶ Briefly, plasma samples were obtained from all participants at their
87 baseline clinical examinations and stored at -80°C . Samples were assayed and concentrations of
88 85 biomarkers were quantified using a modified ELISA sandwich approach on a Luminex xMAP
89 platform (Sigma-Aldrich, St. Louis, MO); 71 of these had detectable levels in at least 95% of
90 participant samples and were used in the present analyses. The 71 protein biomarkers used in this
91 study and their molecular weights are presented in **Supplemental Table 1**. Due to the
92 distribution of protein concentration values, inverse-rank normalized protein concentration
93 values were used in all statistical analyses.

94 Kidney function traits

95 Serum creatinine was measured using the modified Jaffe method (Roche Diagnostics,
96 Indianapolis, IN) and calibrated to National Health and Nutrition Examination Survey

CVD biomarkers and kidney function

97 (NHANES) III creatinine values.⁶ eGFR, an estimate of kidney function, was calculated using
98 the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation.⁵ The annual change in
99 eGFR (Δ eGFR) was calculated for each participant as the follow-up minus baseline eGFR value
100 divided by the number of years between the two visits.

101 This study primarily focused on the continuous eGFR and Δ eGFR measures of kidney
102 function, with a secondary emphasis on dichotomous traits of CKD and rapid decline in eGFR.
103 Participants were categorized as having CKD stage ≥ 3 at the baseline visit if they had eGFR
104 values <60 mL/min/1.73m². New-onset CKD stage ≥ 3 was defined as a follow-up eGFR <60
105 mL/min/1.73m² in participants who had eGFR values ≥ 60 mL/min/1.73m² at baseline and a
106 concomitant $\geq 30\%$ reduction in eGFR between baseline and follow-up.²² Rapid decline in eGFR
107 was defined as a decline in eGFR of at least 3 mL/min/1.73m² per year between baseline and
108 follow-up.

109 Meta-analyzed GWAS of kidney function traits

110 Publicly available kidney trait GWAS summary statistics were obtained from the
111 CKDGen Consortium website (<https://ckdgen.imbi.uni-freiburg.de/>) as reported in a 2019 meta-
112 analysis that identified genetic variants associated with eGFR and CKD (eGFR < 60
113 mL/min/1.73m²) in trans-ethnic and European Ancestry populations.¹⁷

114 Association of protein biomarkers with kidney traits

115 The primary kidney function outcomes were cross-sectional eGFR at the baseline visit,
116 and longitudinal Δ eGFR (i.e., eGFR at follow-up minus eGFR at baseline). The statistical
117 associations of each protein biomarker with these traits were evaluated using linear mixed
118 models.

CVD biomarkers and kidney function

119 The secondary kidney function outcomes evaluated were cross-sectional CKD at the
120 baseline visit, new-onset CKD at follow-up, and longitudinal rapid decline in eGFR. The
121 statistical associations between variation in the protein distribution and these dichotomous
122 kidney function traits were evaluated using logistic regression models.

123 All multivariable models were adjusted for the following kidney dysfunction risk factors
124 at baseline: age, sex, BMI, systolic blood pressure, total and HDL cholesterol, blood pressure
125 and/or lipid medication use, prevalent CVD, DM, and cigarette smoking status (current smokers
126 vs. non-smokers). Longitudinal analyses (i.e., models evaluating Δ eGFR, new-onset CKD, and
127 rapid decline in eGFR) were additionally adjusted for baseline eGFR, and only those participants
128 with available longitudinal data and who had a baseline eGFR ≥ 60 mL/min/1.73m² were
129 included in the model assessing new-onset CKD (n=2,257). We defined a “clinical model”
130 including all covariates except the protein biomarker of interest (i.e., reduced model), and a “full
131 model” including all covariates in the clinical model and the protein biomarker of interest.

132 For each protein biomarker, we evaluated the quantitative contribution of the protein
133 biomarker to variation in continuous kidney trait outcomes by comparing the goodness-of-fit R^2
134 value of the main and full models. The change in R^2 (ΔR^2) illustrates the incremental impact of
135 the addition of the protein biomarker over and above the clinical model. For the dichotomous
136 kidney function traits, we compared receiver operating characteristic (ROC) curves between the
137 clinical and full models using a contrast matrix to quantify the difference in the area under the
138 empirical ROC curve (i.e., the c-statistic). Results of the ROC curve comparison fit a chi-square
139 distribution, which was used to evaluate statistical significance. We calculated the false
140 discovery rate (FDR) for all associations, and FDR values <0.05 were interpreted as statistically

CVD biomarkers and kidney function

141 significant. Discovery protein-trait statistical analyses were performed in SAS version 9.4 (SAS
142 Institute, Cary, NC).

143 Validation of continuous kidney function outcomes

144 We conducted internal validation of the protein biomarkers significantly associated with
145 eGFR in cross-sectional discovery analysis and with Δ eGFR in longitudinal discovery analyses.
146 Protein biomarkers that were significantly associated with eGFR in the FHS Offspring cohort
147 were subsequently validated in 3,951 participants in the FHS Third Generation cohort²³ using
148 data from the first (2002-2005) and second (2009-2011) exams of this cohort. Third Generation
149 cohort participants were included in the internal validation sample if they had serum creatinine
150 and the SABRe plasma protein measurements and did not have a medical record-confirmed
151 diagnosis of heart failure or myocardial infarction. Statistical significance of the internal
152 validation analyses was defined as a Bonferroni-corrected p-value of 0.05/total number of
153 proteins included in the validation analysis. Validation analyses were performed in SAS version
154 9.4 (SAS Institute, Cary, NC).

155 Two-sample Mendelian randomization (MR)

156 We used a two-sample MR approach²⁴ to test the hypothesis that protein concentrations
157 associated with eGFR in the discovery and validation protein-trait analyses are causally related
158 to continuous eGFR using data from published kidney trait GWAS.¹⁷ Prior genome-wide
159 association studies (GWAS) of SABRe proteins in FHS participants identified protein
160 quantitative trait loci (pQTL) variants for 57 of the 71 protein biomarkers.²⁵ Of these previously
161 identified variants, we considered only *cis*-pQTL variants for protein biomarkers that were
162 significantly associated with cross-sectional eGFR or longitudinal Δ eGFR in the validation
163 analysis in the Third Generation cohort. *cis*-pQTL variants were defined as those single

CVD biomarkers and kidney function

164 nucleotide polymorphisms (SNPs) that were located 1 megabase upstream or downstream of the
165 protein-coding gene's transcription start site. Furthermore, *cis*-pQTL variants were pruned at
166 linkage disequilibrium $r^2 < 0.01$, and only those that overlapped with SNPs from the kidney
167 function GWAS were used as instrumental variables for the protein biomarkers.

168 For protein biomarkers with only one pQTL variant as an instrumental variant in MR
169 analysis after pruning, the causal effect was calculated using the Wald test. For protein
170 biomarkers with more than one pQTL variant after pruning, the causal effect was calculated
171 using inverse-variance weighted meta-analyzed estimates. MR results were interpreted as
172 statistically significant after applying a Bonferroni correction for the total number of unique
173 protein biomarkers tested across all outcomes (i.e., $p < 0.05/n$, where n is the number of protein-
174 trait associations tested).

175 In the case of multiple *cis*-pQTL variants contributing to a significant weighted causal
176 estimate, we conducted sensitivity analyses for heterogeneity. When more than two pQTL
177 variants or SNPs contributed to a significant weighted causal estimate, we additionally tested for
178 horizontal pleiotropy and evaluated the change in the effect estimate after excluding one variant
179 at a time from the calculation (i.e., leave-one-out analysis).

180 All MR analyses were conducted in R version 4.0.2 using the *TwoSampleMR*
181 package.^{24,26}

182 **Results**

183 Participant characteristics

184 Baseline characteristics of participants in the FHS Offspring and Third Generation cross-
185 sectional cohorts are presented in **Table 1**. The mean age of participants in the Offspring cohort
186 was 60 ± 9 years and mean eGFR was 84 ± 16 mL/min/1.73m². Seven percent of the Offspring

CVD biomarkers and kidney function

187 cohort had CKD at baseline, while the prevalence of DM and hypertension were 10% and 43%,
188 respectively. The mean age of participants in the Third Generation cohort was 40 ± 9 years and
189 mean eGFR was 102 ± 14 mL/min/1.73m². Less than one percent of the Third Generation cohort
190 sample had CKD, while the prevalence of DM and hypertension were 3% and 18%, respectively.

191 Follow-up characteristics of FHS Offspring (discovery) cohort participants included in
192 longitudinal analysis of Δ eGFR, new-onset CKD, and rapid decline in eGFR are presented in
193 **Supplemental Table 2**. The mean age of Offspring cohort participants at follow-up was 66 ± 9
194 years and mean annual Δ eGFR between baseline and follow-up was -0.97 ± 1.73
195 mL/min/1.73m². Among participants who did not have CKD at baseline, 3% experienced new-
196 onset CKD during follow-up while 91% maintained their eGFR at over 60 mL/min/1.73m². The
197 remaining participants had a follow-up eGFR < 60 mL/min/1.73m², but had a reduction in eGFR
198 $< 30\%$. Eleven percent of the Offspring cohort sample included in longitudinal analysis
199 experienced rapid decline in eGFR between baseline and follow-up.

200 Discovery and validation of cross-sectional and longitudinal protein-eGFR associations

201 Cross-sectional associations of each of the 71 protein biomarkers with eGFR and the
202 incremental increase in model R^2 associated with each protein biomarker are presented in
203 **Supplemental Table 3**. Thirty-seven protein biomarkers were significantly associated with
204 eGFR (at FDR <0.05) in cross-sectional analysis, and of these, all but one (butyrylcholine
205 esterase) had an inverse association with eGFR. Six protein biomarkers were significantly
206 associated with a change in $R^2 \geq 5\%$, including alpha-1-microglobulin (A1M), adipsin, beta-2-
207 microglobulin (B2M), cystatin C, myoglobin, and resistin. Of the 37 protein biomarkers that
208 were significantly associated with eGFR in the Offspring cohort in cross-sectional analysis, 20

CVD biomarkers and kidney function

209 were also significantly associated with eGFR in the Third Generation cohort at
210 $p=0.05/37=0.00135$ (**Supplemental Table 4**).

211 Longitudinal associations of each of the 71 protein biomarkers with Δ eGFR and the
212 incremental increase in model R^2 associated with each protein biomarker are presented in
213 **Supplemental Table 5**. Twenty-seven protein biomarkers were significantly associated with
214 Δ eGFR at $FDR<0.05$. All significant protein biomarkers except two (plasminogen activator
215 inhibitor 1 [PAI1] and dipeptidyl dipeptidase [DPP4]) were inversely associated with Δ eGFR.
216 B2M and cystatin C were associated with the largest increases in R^2 ($\Delta R^2 = 3.3\%$ and 2.5% ,
217 respectively). Of the 27 proteins that were significantly associated with Δ eGFR in the Offspring
218 cohort in longitudinal analysis, 12 were also significantly associated with Δ eGFR in the Third
219 Generation cohort at $p=0.05/27=0.00185$ (**Supplemental Table 6**).

220 Discovery protein-trait associations: Cross-sectional associations with secondary outcomes in the 221 Offspring cohort

222 Cross-sectional associations of each of the 71 protein biomarkers with prevalent CKD
223 and the associated change in the C-statistic are presented in **Supplemental Table 7**. Thirty-five
224 protein biomarkers were significantly associated with prevalent CKD at $FDR<0.05$, and of these,
225 all but one (angiopoietin-like 3) were associated with greater log-odds of CKD. Ten protein
226 biomarkers were associated with a statistically significant change in the C-statistic.

227 Discovery protein-trait associations: Longitudinal associations with secondary outcomes in the 228 Offspring cohort

229 Five protein biomarkers were significantly associated with higher log-odds of new-onset
230 CKD at $FDR<0.05$ (**Supplemental Table 8**), while 17 protein biomarkers were significantly
231 associated with higher log-odds of rapid decline in eGFR (**Supplemental Table 9**). No

CVD biomarkers and kidney function

232 biomarkers were associated with a significant increase in the model C-statistic for either rapid
233 decline in eGFR or new-onset CKD.

234 Causal inference

235 Twenty-four unique proteins were significantly associated with eGFR in both the
236 Offspring and Third Generation in cross-sectional and/or longitudinal analyses; therefore,
237 statistical significance for all MR analyses was set at a Bonferroni-corrected p-value of $0.05/24 =$
238 0.00208 . The 24 protein biomarkers associated with eGFR had a total of 25 *cis*-pQTL variants
239 that overlapped with SNPs in the eGFR GWAS¹⁷ and were included in MR analyses. Significant
240 results of MR analysis (protein → kidney trait) for proteins that were significantly associated
241 with eGFR or with Δ eGFR are presented in **Table 3**; full MR results for all protein biomarkers
242 with *cis*-pQTL variants are presented in **Supplemental Table 10**. Higher concentrations of
243 epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) and
244 melanoma cell adhesion molecule (MCAM) were significantly associated with lower eGFR ($\beta \pm$
245 $SE -0.0064 \pm 0.0016$ and -0.0111 ± 0.0027 , respectively), consistent with a potentially causal
246 relationship. Sensitivity analysis of the two EFEMP1 pQTL variants indicated no heterogeneity
247 ($p=0.69$, **Supplemental Table 9**).

248 **Discussion/Conclusion**

249 We identified a total of 43 CVD-related protein biomarkers associated with eGFR, a
250 continuous measure of kidney function, in cross-sectional and/or longitudinal discovery analysis.
251 Among these, eight proteins were significantly associated with both eGFR and Δ eGFR in the
252 FHS Offspring discovery sample and the FHS Third Generation validation sample. Of the 37
253 proteins associated with eGFR and 27 proteins associated with Δ eGFR in the FHS Offspring
254 cohort (i.e. discovery), 20 and 12 were associated with the corresponding trait in the FHS Third

CVD biomarkers and kidney function

255 Generation cohort (i.e. validation). This group of protein biomarkers included EFEMP1 and
256 MCAM, which were putatively causally related to eGFR in MR analysis. To our knowledge,
257 causal relations of protein biomarkers to CKD based on an integrative genomic approach have
258 not been reported previously.

259 CKD and CVD share several risk factors; identifying early mechanisms linking the two
260 disease processes may provide insights into targeted interventions to prevent or delay the onset
261 of clinically overt disease. The most notable shared risk factors are DM and hypertension. DM is
262 associated with systemic inflammation and oxidative stress,²⁷ which in turn are associated with
263 microvascular and macrovascular complications and kidney damage.^{28,29} Hypertension results in
264 prolonged exposure of the heart, kidney, and vasculature to elevated hemodynamic load that can
265 contribute to left ventricular hypertrophy, vascular stiffening, heart failure, and CKD.³⁰ Over-
266 activation of the renin-angiotensin-aldosterone system, which increases blood pressure through
267 multiple mechanisms, can damage glomerular cells.¹³ Treatment of hypertension can prevent
268 CKD progression,³¹ while conversely, kidney disease can lead to resistant hypertension.³²
269 Furthermore, inflammation also contributes to development of both CKD and CVD. In CKD, the
270 concentration of inflammatory proteins is inversely related to eGFR, and the cytokine interleukin
271 (IL)-6 is a reliable predictor of adverse clinical outcomes in individuals with CKD.^{14,33,34} Chronic
272 inflammation also may cause oxidative stress and endothelial dysfunction, which contribute to
273 microvascular damage, new-onset or worsening CKD, and clinical CVD.¹⁵

274 The eGFR values observed in the FHS Offspring participants included in the discovery
275 stage of this study were mostly in the normal range and few individuals experience a rapid
276 decline in eGFR (n=265; 11%) or progressed to new-onset CKD (n=72; 3%) during follow-up.
277 Under normal conditions, the glomerulus is able to freely filter proteins with molecular weight

CVD biomarkers and kidney function

278 (MW) < 70 kilodaltons (kDa), and as such, many of the proteins identified in the cross-sectional
279 and longitudinal protein-trait analyses may reflect early impaired kidney clearance of proteins
280 with low molecular weights with a resultant increase in concentrations of circulating proteins.³⁵
281 Indeed, the vast majority of protein biomarkers showed negative associations with eGFR (i.e.,
282 lower eGFR was associated with higher protein levels), thus many of the protein biomarkers
283 identified in this study are likely downstream biomarkers of reduced kidney function.
284 Accordingly, the protein biomarkers with consistent and highly significant associations are well-
285 established markers of kidney function, and our validation in the Third Generation cohort of
286 many of the discovery associations observed in the Offspring cohort emphasize associations of
287 these proteins with kidney function in a younger, healthier population with little prevalent CKD.
288 Eight protein biomarkers were associated with both eGFR and Δ eGFR in both the Offspring and
289 Third Generation cohorts, including adipsin, adrenomedullin (ADM), A1M, B2M, collagen type
290 XVIII alpha 1 (COL18A1), cystatin C, EFEMP1, and fibroblast growth factor 23 (FGF23). Of
291 these, cystatin C (MW 15.8 kDa) and B2M (MW 13.7 kDa) were associated with all kidney traits
292 and are used in alternative eGFR calculations due to their low MW and their role as early
293 indicators of kidney impairment, and they are additionally associated with CVD outcomes.^{16,36–39}
294 Other protein biomarkers significantly associated with eGFR and Δ eGFR are also associated
295 with inflammation and kidney disease and may represent non-traditional markers of kidney
296 function due to parallel mechanisms relevant also to CVD. A1M (MW 29.8 kDa), while having a
297 slightly higher MW than either cystatin C or B2M, has also been proposed as a biomarker of
298 kidney disease progression.^{40–42} Similarly, adipsin (MW 27.0 kDa), ADM (MW 20.4 kDa),
299 FGF23 (MW 28.0 kDa), and endostatin, a 20 kDa fragment of the 178.2 kDa COL18A1, were all
300 reported to be elevated in the setting of kidney disease in prior studies.^{43–47} These protein

CVD biomarkers and kidney function

301 biomarkers showed a robust association with kidney traits and it is possible that they reflect
302 CKD risk early in the subclinical disease process.

303 We hypothesized *a priori* that a subset of proteins associated with kidney function may
304 be causal contributors to renal impairment. A recent MR analysis suggested a putatively causal
305 role of melanoma-derived growth regulatory protein (MIA), cystatin M, and carbonic anhydrase
306 III in kidney disease.⁵⁵ While these proteins were not included in our assay, our MR analysis
307 evaluated 24 new protein biomarkers and revealed putatively causal inverse relations of
308 EFEMP1 and MCAM with eGFR. EFEMP1 is an extracellular matrix protein involved in both
309 cellular structure and signaling, and it was associated with worse eGFR cross-sectionally and
310 with Δ eGFR longitudinally, with prevalent CKD, and with rapid decline in eGFR. A prior study
311 reported elevated EFEMP1 concentration in human kidney tissue with immunoglobulin A (IgA)
312 nephropathy.⁵⁶ The causal mechanism is still unclear, but animal models suggest that EFEMP1
313 may be associated with vascular remodeling in hypertension.⁵⁷ MCAM, also known as MUC18
314 or CD146, is expressed in endothelial cells and is significantly elevated in individuals with
315 diabetic nephropathy^{58,59} and CKD.^{60,61} Results of our protein-trait analysis similarly showed an
316 association between MCAM with both eGFR and CKD in cross-sectional analyses.

317 This study has several limitations that must be noted. The primary limitation is that a
318 custom assay used to measure the protein biomarkers in this study, which limited external
319 replication of our results. To address this limitation, we performed validation of the discovery
320 results from the FHS Offspring cohort in participants from the younger and healthier Third
321 Generation cohort in whom CKD was rare (0.3% prevalent CKD at baseline). Independent
322 external replication of the protein biomarkers identified in this study is needed.

CVD biomarkers and kidney function

323 In addition, we estimated kidney function based on a single creatinine measurement at
324 both baseline and follow-up, rather than using multiple eGFR values at each time point. As such,
325 our definition of CKD stage ≥ 3 does not mirror the recommended clinical diagnosis of CKD,
326 which requires the presence of kidney structural or functional abnormalities for at least three
327 months.⁶² Furthermore, the younger and healthier cohort used for validation analyses limited our
328 ability to identify protein biomarkers of changing kidney function and CKD in longitudinal
329 analysis. Albuminuria and blood urea nitrogen may be clinically useful in the evaluation of
330 patients with impaired kidney function, but these data were not available for analysis in this
331 study. Our study population was limited to adults of European ancestry, which may limit
332 generalizability to other ancestry groups. Functional studies of the proteins reported to have
333 putatively causal relations to kidney function in this investigation may be warranted.

334 The primary strengths of this study are the large sample size and the integrative genomic
335 approach we employed. We reported cross-sectional and longitudinal protein-trait association
336 results to identify numerous proteins associated with kidney function and its change over time.
337 By integrating pQTL data for the proteins we measured with genetic variants from large GWAS
338 of kidney disease traits we identified putatively causal proteins for kidney function that represent
339 promising candidates for further studies with the ultimate goal to better treat or prevent CKD.

340 The results of the comprehensive cross-sectional and longitudinal analyses in this study
341 validate proteins that may detect of impaired kidney function early in the disease process when
342 treatment is most likely to be beneficial. We identified robust, significant associations between
343 20 protein biomarkers with eGFR in cross-sectional discovery and validation analyses and 12
344 proteins with Δ eGFR in longitudinal analyses both in discovery and validation. Additionally, two
345 proteins were found to be putatively causal for reduced kidney function in causal inference

CVD biomarkers and kidney function

346 testing. Further studies are necessary to determine if any of the proteins identified by MR can
347 serve as useful biomarkers for CKD either individually or in combination with known and
348 validated biomarkers.
349

CVD biomarkers and kidney function

350 **References**

- 351 1. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2017 Annual Data Report:
352 Epidemiology of Kidney Disease in the United States. *Am J kidney Dis Off J Natl Kidney*
353 *Found.* 2018;71(3 Suppl 1):A7. doi:10.1053/j.ajkd.2018.01.002
- 354 2. Joubert BR, Felix JF, Yousefi P, et al. DNA Methylation in Newborns and Maternal
355 Smoking in Pregnancy: Genome-wide Consortium Meta-analysis. *Am J Hum Genet.*
356 2016;98(4):680-696. doi:<https://doi.org/10.1016/j.ajhg.2016.02.019>
- 357 3. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic
358 kidney disease, 1990–2017: a systematic analysis for the Global Burden of
359 Disease Study 2017. *Lancet.* 2020;395(10225):709-733. doi:10.1016/S0140-
360 6736(20)30045-3
- 361 4. Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher
362 albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis
363 of general and high-risk population cohorts. *Kidney Int.* 2011;80(1):93-104.
364 doi:10.1038/ki.2010.531
- 365 5. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular
366 filtration rate. *Ann Intern Med.* 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-
367 200905050-00006
- 368 6. Fox CS, Larson MG, Leip EP, Cullerton B, Wilson PWF, Levy D. Predictors of New-
369 Onset Kidney Disease in a Community-Based Population. *JAMA.* 2004;291(7):844-850.
370 doi:10.1001/jama.291.7.844
- 371 7. Flint AC, Conell C, Ren X, et al. Effect of Systolic and Diastolic Blood Pressure on
372 Cardiovascular Outcomes. *N Engl J Med.* 2019;381(3):243-251.

CVD biomarkers and kidney function

- 373 doi:10.1056/NEJMoa1803180
- 374 8. Dokken BB. The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood
375 Pressure and Lipids. *Diabetes Spectr.* 2008;21(3):160 LP - 165.
376 doi:10.2337/diaspect.21.3.160
- 377 9. Zelnick LR, Weiss NS, Kestenbaum BR, et al. Diabetes and CKD in the United States
378 Population, 2009–2014. *Clin J Am Soc Nephrol.* 2017;12(12):1984 LP - 1990.
379 doi:10.2215/CJN.03700417
- 380 10. United States Renal Data System. *2020 USRDS Annual Data Report: Epidemiology of*
381 *Kidney Disease in the United States.*; 2020.
- 382 11. Kibria GM Al, Crispen R. Prevalence and trends of chronic kidney disease and its risk
383 factors among US adults: An analysis of NHANES 2003-18. *Prev Med reports.*
384 2020;20:101193. doi:10.1016/j.pmedr.2020.101193
- 385 12. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance
386 System—United States. Published 2020. <http://www.cdc.gov/ckd>
- 387 13. Gajjala PR, Sanati M, Jankowski J. Cellular and Molecular Mechanisms of Chronic
388 Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities.
389 *Front Immunol.* 2015;6:340. doi:10.3389/fimmu.2015.00340
- 390 14. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J. Oxidative
391 stress and inflammation, a link between chronic kidney disease and cardiovascular
392 disease: New strategies to prevent cardiovascular risk in chronic kidney disease. *Kidney*
393 *Int.* 2008;74:S4-S9. doi:10.1038/ki.2008.516
- 394 15. Podkowińska A, Formanowicz D. Chronic Kidney Disease as Oxidative Stress- and
395 Inflammatory-Mediated Cardiovascular Disease. *Antioxidants (Basel, Switzerland).*

CVD biomarkers and kidney function

- 396 2020;9(8):752. doi:10.3390/antiox9080752
- 397 16. Ho JE, Lyass A, Courchesne P, et al. Protein Biomarkers of Cardiovascular Disease and
398 Mortality in the Community. *J Am Heart Assoc.* 2018;7(14):e008108.
399 doi:10.1161/JAHA.117.008108
- 400 17. Wuttke M, Li Y, Li M, et al. A catalog of genetic loci associated with kidney function
401 from analyses of a million individuals. *Nat Genet.* 2019;51(6):957-972.
402 doi:10.1038/s41588-019-0407-x
- 403 18. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of
404 coronary heart disease in families: the Framingham Offspring Study. *Am J Epidemiol.*
405 1979;110(3):281-290. doi:10.1093/oxfordjournals.aje.a112813
- 406 19. Tsao CW, Vasan RS. Cohort Profile: The Framingham Heart Study (FHS): overview of
407 milestones in cardiovascular epidemiology. *Int J Epidemiol.* 2015;44(6):1800-1813.
408 doi:10.1093/ije/dyv337
- 409 20. Association AD. 2. Classification and Diagnosis of Diabetes: Standards of
410 Medical Care in Diabetes—2020 *Diabetes Care.* 2020;43(Supplement 1):S14
411 LP-S31. doi:10.2337/dc20-S002
- 412 21. Chobanian A V, Bakris GL, Black HR, et al. Seventh Report of the Joint National
413 Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
414 *Hypertension.* 2003;42(6):1206-1252. doi:10.1161/01.HYP.0000107251.49515.c2
- 415 22. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in
416 CKD: a scientific workshop sponsored by the National Kidney Foundation and the US
417 Food and Drug Administration. *Am J kidney Dis Off J Natl Kidney Found.*
418 2014;64(6):821-835. doi:10.1053/j.ajkd.2014.07.030

CVD biomarkers and kidney function

- 419 23. Splansky GL, Corey D, Yang Q, et al. The Third Generation Cohort of the National Heart,
420 Lung, and Blood Institute's Framingham Heart Study: Design, Recruitment, and Initial
421 Examination. *Am J Epidemiol.* 2007;165(11):1328-1335. doi:10.1093/aje/kwm021
- 422 24. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal
423 inference across the human phenome. *Elife.* 2018;7. doi:10.7554/eLife.34408
- 424 25. Yao C, Chen G, Song C, et al. Genome-wide mapping of plasma protein QTLs identifies
425 putatively causal genes and pathways for cardiovascular disease. *Nat Commun.*
426 2018;9(1):3268. doi:10.1038/s41467-018-05512-x
- 427 26. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
428 imprecisely measured traits using GWAS summary data. *PLoS Genet.*
429 2017;13(11):e1007081. doi:10.1371/journal.pgen.1007081
- 430 27. Odegaard AO, Jacobs DRJ, Sanchez OA, Goff DCJ, Reiner AP, Gross MD. Oxidative
431 stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes.
432 *Cardiovasc Diabetol.* 2016;15:51. doi:10.1186/s12933-016-0369-6
- 433 28. Lv W, Booz GW, Wang Y, Fan F, Roman RJ. Inflammation and renal fibrosis: Recent
434 developments on key signaling molecules as potential therapeutic targets. *Eur J*
435 *Pharmacol.* 2018;820:65-76. doi:10.1016/j.ejphar.2017.12.016
- 436 29. Jha JC, Ho F, Dan C, Jandeleit-Dahm K. A causal link between oxidative stress and
437 inflammation in cardiovascular and renal complications of diabetes. *Clin Sci (Lond).*
438 2018;132(16):1811-1836. doi:10.1042/CS20171459
- 439 30. Nwabuo CC, Appiah D, Moreira HT, et al. Long-term cumulative blood pressure in young
440 adults and incident heart failure, coronary heart disease, stroke, and cardiovascular
441 disease: The CARDIA study. *Eur J Prev Cardiol.* Published online April

CVD biomarkers and kidney function

- 442 2020:2047487320915342. doi:10.1177/2047487320915342
- 443 31. Ptinopoulou AG, Pikilidou MI, Lasaridis AN. The effect of antihypertensive drugs on
444 chronic kidney disease: a comprehensive review. *Hypertens Res.* 2013;36(2):91-101.
445 doi:10.1038/hr.2012.157
- 446 32. Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation,
447 and Management: A Scientific Statement From the American Heart Association.
448 *Hypertens (Dallas, Tex 1979).* 2018;72(5):e53-e90.
449 doi:10.1161/HYP.0000000000000084
- 450 33. Sun J, Axelsson J, Machowska A, et al. Biomarkers of Cardiovascular Disease and
451 Mortality Risk in Patients with Advanced CKD. *Clin J Am Soc Nephrol.* 2016;11(7):1163-
452 1172. doi:10.2215/CJN.10441015
- 453 34. Gupta J, Mitra N, Kanetsky PA, et al. Association between albuminuria, kidney function,
454 and inflammatory biomarker profile in CKD in CRIC. *Clin J Am Soc Nephrol.*
455 2012;7(12):1938-1946. doi:10.2215/CJN.03500412
- 456 35. Strober W, Waldmann TA. The role of the kidney in the metabolism of plasma proteins.
457 *Nephron.* 1974;13(1):35-66. doi:10.1159/000180368
- 458 36. Argyropoulos CP, Chen SS, Ng Y-H, et al. Rediscovering Beta-2 Microglobulin As a
459 Biomarker across the Spectrum of Kidney Diseases. *Front Med.* 2017;4:73.
460 doi:10.3389/fmed.2017.00073
- 461 37. Joseph Y, N. BE, C. MA, et al. Impact of Kidney Function on the Blood Proteome and on
462 Protein Cardiovascular Risk Biomarkers in Patients With Stable Coronary Heart Disease.
463 *J Am Heart Assoc.* 2020;9(15):e016463. doi:10.1161/JAHA.120.016463
- 464 38. Liu X, Foster MC, Tighiouart H, et al. Non-GFR Determinants of Low-Molecular-Weight

CVD biomarkers and kidney function

- 465 Serum Protein Filtration Markers in CKD. *Am J kidney Dis Off J Natl Kidney Found.*
466 2016;68(6):892-900. doi:10.1053/j.ajkd.2016.07.021
- 467 39. Christensson A, Ash JA, DeLisle RK, et al. The Impact of the Glomerular Filtration Rate
468 on the Human Plasma Proteome. *PROTEOMICS – Clin Appl.* 2018;12(3):1700067.
469 doi:<https://doi.org/10.1002/prca.201700067>
- 470 40. Luczak M, Formanowicz D, Pawliczak E, Wanic-Kossowska M, Wykretowicz A,
471 Figlerowicz M. Chronic kidney disease-related atherosclerosis - proteomic studies of
472 blood plasma. *Proteome Sci.* 2011;9:25. doi:10.1186/1477-5956-9-25
- 473 41. Jotwani V, Katz R, Ix JH, et al. Urinary Biomarkers of Kidney Tubular Damage and Risk
474 of Cardiovascular Disease and Mortality in Elders. *Am J Kidney Dis.* 2018;72(2):205-213.
475 doi:10.1053/j.ajkd.2017.12.013
- 476 42. Vyssoulis GP, Tousoulis D, Antoniadis C, Dimitrakopoulos S, Zervoudaki A, Stefanadis
477 C. α -1 Microglobulin as a New Inflammatory Marker in Newly Diagnosed Hypertensive
478 Patients: . *Am J Hypertens.* 2007;20(9):1016-1021. doi:10.1016/j.amjhyper.2007.01.010
- 479 43. Volanakis JE, Barnum SR, Giddens M, Galla JH. Renal Filtration and Catabolism of
480 Complement Protein D. *N Engl J Med.* 1985;312(7):395-399.
481 doi:10.1056/NEJM198502143120702
- 482 44. Velho G, Ragot S, Mohammedi K, et al. Plasma Adrenomedullin and Allelic Variation in
483 the ADM Gene and Kidney Disease in People With Type 2 Diabetes. *Diabetes.*
484 2015;64(9):3262-3272. doi:10.2337/db14-1852
- 485 45. Fliser D, Kollerits B, Neyer U, et al. Fibroblast Growth Factor 23 (FGF23) Predicts
486 Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD)
487 Study. *J Am Soc Nephrol.* 2007;18(9):2600 LP - 2608. doi:10.1681/ASN.2006080936

CVD biomarkers and kidney function

- 488 46. Dieplinger B, Mueller T, Kollerits B, et al. Pro-A-type natriuretic peptide and pro-
489 adrenomedullin predict progression of chronic kidney disease: the MMKD Study. *Kidney*
490 *Int.* 2009;75(4):408-414. doi:10.1038/ki.2008.560
- 491 47. Pena MJ, Heinzl A, Heinze G, et al. A panel of novel biomarkers representing different
492 disease pathways improves prediction of renal function decline in type 2 diabetes. *PLoS*
493 *One.* 2015;10(5):e0120995-e0120995. doi:10.1371/journal.pone.0120995
- 494 48. Lau ES, Paniagua SM, Zarbafian S, et al. Cardiovascular Biomarkers of Obesity and
495 Overlap With Cardiometabolic Dysfunction. *J Am Heart Assoc.* 2021;10(14):e020215-
496 e020215. doi:10.1161/JAHA.120.020215
- 497 49. Lampón N, Hermida-Cadahia EF, Riveiro A, Tutor JC. Association between
498 butyrylcholinesterase activity and low-grade systemic inflammation. *Ann Hepatol.*
499 2012;11(3):356-363.
- 500 50. Małgorzewicz S, Skrzypczak-Jankun E, Jankun J. Plasminogen activator inhibitor-1 in
501 kidney pathology (Review). *Int J Mol Med.* 2013;31(3):503-510.
502 doi:10.3892/ijmm.2013.1234
- 503 51. Eddy AA, Fogo AB. Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease:
504 Evidence and Mechanisms of Action. *J Am Soc Nephrol.* 2006;17(11):2999 LP - 3012.
505 doi:10.1681/ASN.2006050503
- 506 52. Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of
507 dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. *Clin Sci (Lond).*
508 2018;132(4):489-507. doi:10.1042/CS20180031
- 509 53. Ma L-J, Fogo AB. PAI-1 and kidney fibrosis. *Front Biosci (Landmark Ed.* 2009;14:2028-
510 2041. doi:10.2741/3361

CVD biomarkers and kidney function

- 511 54. Shi S, Koya D, Kanasaki K. Dipeptidyl peptidase-4 and kidney fibrosis in diabetes.
512 *Fibrogenesis Tissue Repair*. 2016;9(1):1. doi:10.1186/s13069-016-0038-0
- 513 55. Matías-García PR, Wilson R, Guo Q, et al. Plasma Proteomics of Renal Function: A
514 Transethnic Meta-Analysis and Mendelian Randomization Study. *J Am Soc Nephrol*.
515 2021;32(7):1747 LP - 1763. doi:10.1681/ASN.2020071070
- 516 56. Paunas FTI, Finne K, Leh S, et al. Characterization of glomerular extracellular matrix in
517 IgA nephropathy by proteomic analysis of laser-captured microdissected glomeruli. *BMC*
518 *Nephrol*. 2019;20(1):410. doi:10.1186/s12882-019-1598-1
- 519 57. Lin Z, Wang Z, Li G, Li B, Xie W, Xiang D. Fibulin-3 may improve vascular health
520 through inhibition of MMP-2/9 and oxidative stress in spontaneously hypertensive rats.
521 *Mol Med Rep*. 2016;13(5):3805-3812. doi:10.3892/mmr.2016.5036
- 522 58. Fan Y, Fei Y, Zheng L, et al. Expression of Endothelial Cell Injury Marker Cd146
523 Correlates with Disease Severity and Predicts the Renal Outcomes in Patients with
524 Diabetic Nephropathy. *Cell Physiol Biochem*. 2018;48(1):63-74. doi:10.1159/000491663
- 525 59. Saito T, Saito O, Kawano T, et al. Elevation of serum adiponectin and CD146 levels in
526 diabetic nephropathy. *Diabetes Res Clin Pract*. 2007;78(1):85-92.
527 doi:10.1016/j.diabres.2007.02.014
- 528 60. Bardin N, Moal V, Anfosso F, et al. Soluble CD146, a novel endothelial marker, is
529 increased in physiopathological settings linked to endothelial junctional alteration.
530 *Thromb Haemost*. 2003;90(5):915-920. doi:10.1160/TH02-11-0285
- 531 61. Wang N, Fan Y, Ni P, et al. High glucose effect on the role of CD146 in human proximal
532 tubular epithelial cells in vitro. *J Nephrol*. 2008;21(6):931-940.
- 533 62. Levin A, Stevens P, Bilous RW, et al. Kidney disease: Improving global outcomes

CVD biomarkers and kidney function

534 (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation

535 and management of chronic kidney disease. *Kidney Int Suppl.* 2013;3:1-150.

536 doi:10.1038/kisup.2012.73

537

538

CVD biomarkers and kidney function

539 **Statements**

540 **Statement of ethics:** The study protocol was reviewed and approved by the Boston University
541 Medical Center Institutional Review Board. All study participants provided their written
542 informed consent for their data and biological samples to be used.

543 **Conflict of interest statement:** The authors have no conflicts of interest to declare.

544 **Funding sources:** The Framingham Heart Study laboratory work for this project was funded by
545 National Institutes of Health contract N01-HC-25195. The analytical component of this project
546 was funded by the Division of Intramural Research, National Heart, Lung, and Blood Institute,
547 National Institutes of Health, Bethesda, MD (D. Levy, Principal Investigator). The work of A
548 Köttgen was funded by the Deutsche Forschungsgesellschaft (DFG, German Research
549 Foundation) – Project-ID 431984000 – SFB 1453.

550 **Disclaimer:** The views expressed in this manuscript are those of the authors and do not
551 necessarily represent the views of the National Heart, Lung, and Blood Institute; the National
552 Institutes of Health; or the U.S. Department of Health and Human Services.

553 **Author contributions:** A Keshawarz, GY Lee, S Hwang, Z Yu, and C Yao contributed to data
554 analysis. All authors contributed to data interpretation. GY Lee, S Hwang, A Köttgen, and D
555 Levy conceived the research study. A Keshawarz drafted the manuscript. GY Lee, S Hwang, C
556 Yao, A Köttgen, and D Levy provided critical revisions. All authors gave final approval for
557 publication and are the guarantors of this work.

558 **Data availability statement:** The data presented in these analyses can be accessed through the
559 National Center for Biotechnology Information Database of Genotypes and Phenotypes
560 (accession number, phs00007.v29.p10).

561

CVD biomarkers and kidney function

562 Tables

563 Table 1. Baseline demographic and clinical participant characteristics.

Characteristic	Offspring cohort (n=2,873)	Third Generation cohort (n=3,951)
Age, years	60 ± 9	40 ± 9
Women, n (%)	1,573 (55%)	2,109 (53%)
eGFR, mL/min/1.73m ²	84 ± 16	102 ± 14
CKD, n (%)	210 (7%)	10 (0.3%)
BMI, kg/m ²	27.95 ± 5.22	26.87 ± 5.55
Fasting glucose, mg/dL	102.99 ± 24.59	95.02 ± 17.9
Systolic blood pressure, mmHg	126.18 ± 18.54	116.69 ± 14.02
Diastolic blood pressure, mmHg	74.15 ± 9.7	75.26 ± 9.63
Total cholesterol, mg/dL	200.64 ± 36.42	188.81 ± 35.46
HDL cholesterol, mg/dL	54.41 ± 17.2	54.41 ± 16.16
DM, n (%)	280 (10%)	114 (3%)
Hypertension, n (%)	1242 (43%)	726 (18%)
Current cigarette smoker, n (%)	362 (13%)	605 (15%)
Cholesterol-lowering medication use, n (%)	564 (20%)	341 (9%)
Prevalent cardiovascular disease, n (%)	308 (11%)	38 (1%)

564 Abbreviations: eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; BMI, body mass index;

565 HDL, high density lipoprotein; DM, diabetes mellitus

566 All continuous characteristics are presented as mean ± standard deviation. All categorical variables are presented as

567 total n (column %) in that category.

568 **Table 2. Biomarkers associated with eGFR and ΔeGFR in the FHS Offspring and Third Generation cohorts.**

Protein biomarker	Protein biomarker abbreviation	eGFR, Offspring		eGFR, Third Generation		ΔeGFR, Offspring		ΔeGFR, Third Generation	
		β ± SE	FDR	β ± SE	p-value	β ± SE	FDR	β ± SE	p-value
Adipsin	--	-0.09 ± 0.004	<1E-27	-0.04 ± 0.002	<1E-27	-0.22 ± 0.04	7.3E-07	-0.16 ± 0.03	1.2E-06
Alpha-1-microglobulin	A1M	-0.06 ± 0.004	<1E-27	-0.02 ± 0.002	3.5E-12	-0.18 ± 0.04	1.1E-05	-0.17 ± 0.03	3.6E-08
Beta-2-microglobulin	B2M	-0.10 ± 0.004	<1E-27	-0.03 ± 0.002	<1E-27	-0.43 ± 0.04	9.9E-21	-0.13 ± 0.03	3.7E-05
Cystatin C	--	-0.10 ± 0.004	<1E-27	-0.04 ± 0.003	<1E-27	-0.38 ± 0.04	6.8E-16	-0.21 ± 0.03	1.8E-10
Epidermal growth factor containing fibulin-like extracellular matrix protein 1	EFEMP1	-0.05 ± 0.004	1.7E-26	-0.01 ± 0.003	8.7E-4	-0.17 ± 0.04	2.8E-04	-0.18 ± 0.03	1.6E-07
Myoglobin	--	-0.07 ± 0.004	<1E-27	-0.04 ± 0.003	<1E-27	-0.20 ± 0.04	1.5E-05	-0.13 ± 0.04	3.3E-04
Soluble receptor for advanced glycation endproducts	sRAGE	-0.03 ± 0.004	3.0E-14	-0.01 ± 0.002	6.4E-07	-0.10 ± 0.03	0.02	-0.11 ± 0.03	9.4E-05
Tissue inhibitor of metalloproteinases 1	TIMP1	-0.06 ± 0.004	<1E-27	-0.02 ± 0.002	4.4E-16	-0.21 ± 0.04	8.2E-06	-0.14 ± 0.03	4.5E-06

569

570 **Table 3. Causal inference results: MR results for biomarkers significantly associated with eGFR in cross-sectional analyses.**

Protein biomarker exposure	Protein biomarker abbreviation	Kidney trait outcome	n _{snp}	β ± SE	p-value
Melanoma cell adhesion molecule	MCAM	eGFR (continuous)	1	-0.0111 ± 0.0027	5.11E-5
Epidermal growth factor containing fibulin-like extracellular matrix protein 1	EFEMP1	eGFR (continuous)	2	-0.0064 ± 0.0016	1.04E-4

571

572 **Figure legends**

573 **Figure 1.** Overview of the study design.

Study population

Participants with SABRe CVD biomarkers
and kidney function measures
(n=6,824)

Offspring cohort
(n=2,873)

Third Generation cohort
(n=3,951)

Protein-trait associations

Discovery protein-trait associations

Continuous kidney traits

Dichotomous kidney traits

Cross-sectional
eGFR

Longitudinal
 Δ eGFR

Cross-sectional
prevalent CKD

Longitudinal
incident CKD

Rapid decline
in eGFR

Internal validation of
protein associations
with continuous kidney traits

Causal inference

Mendelian randomization